Monitor for any takedown or prospectus supplement under these shelves. If the company announces a secondary offering or at-the-market program, expect significant dilution pressure. The multiple effective shelves increase the likelihood of a capital raise in the near to medium term.
ESPR drugs
ESPR drug pipeline →Price Chart
How similar events traded
Executive Summary
Esperion Therapeutics had four shelf registration statements (File Nos. 333-286631, 333-264303, 333-258396, 333-208701) declared effective by the SEC on July 15, 2026. This gives the company the ability to issue and sell securities at any time, creating a meaningful dilution overhang. The batch of four simultaneous effectiveness notices amplifies the potential for future capital raises, which is a bearish signal given the company's $819M market cap and predominantly hold/sell analyst consensus.
Key Facts
- Four separate shelf registration statements became effective on July 15, 2026.
- File numbers: 333-286631, 333-264303, 333-258396, 333-208701.
- Esperion can now offer and sell securities under these shelves at any time.
- Market cap is approximately $819M with 0% analyst bullish rating.
- Top institutional holder Wasatch Advisors holds $6M and recently showed a near-exit move.
Financial Impact
Potential future dilution from securities offerings under four active shelves; no specific offering size disclosed.
Risk Factors
- Dilutive secondary offering or convertible issuance could materially reduce per-share value.
- Stock overhang may suppress price appreciation until the company clarifies its capital needs.
- Analyst consensus is already bearish, and additional supply could exacerbate selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (ESPR), Batch item 1 | 9999999995-26-002307 |
| Document: 9999999995-26-002307-index.html | 9999999995-26-002305 |
| Document: 9999999995-26-002307.txt | 9999999995-26-002304 |
| EFFECT Filing (ESPR), Batch item 4 | 9999999995-26-002305 |
| Document: 9999999995-26-002305-index.html | 9999999995-26-002307 |
| Document: 9999999995-26-002305.txt | 9999999995-26-002307 |
| EFFECT Filing (ESPR), Batch item 7 | 9999999995-26-002304 |
| Document: 9999999995-26-002304-index.html | 9999999995-26-002307 |
| Document: 9999999995-26-002304.txt | 9999999995-26-002307 |
| EFFECT Filing (ESPR), Batch item 10 | 9999999995-26-002303 |
| Document: 9999999995-26-002303-index.html | 9999999995-26-002307 |
| Document: 9999999995-26-002303.txt | 9999999995-26-002307 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Viewing Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers